Synapse - Works

Results (5608)

First-in-human safety, imaging and dosimetry of [(68(Ga]Ga-DPI-4452, a novel CA IX-targeting peptide, in patients with clear cell renal cell carcinoma

Meeting Abstract

Hofman, M. S.; Tran, B.; Feldman, D. R.; Pokorska-Bocci, A.; Pichereau, S.; Wessen, J.; Haskali, M. B.; Sparks, R.; Vlasyuk, O.; Galetic, I.
Journal of Clinical Oncology (2024)

Fulltext@MSK | Save

Subgroup analyses of efficacy outcomes by baseline tumor size in the phase 3, open-label CLEAR trial

Meeting Abstract

Grünwald, V.; Motzer, R. J.; Haanen, Jbag; Schmidinger, M.; Staehler, M. D.; Goh, J. C.; Voog, E.; Climent, M. A.; George, S.; Burgents, J. E.; more...
Journal of Clinical Oncology (2024)

Fulltext@MSK | Save

Hypoxia-inducible factor-2 alpha (HIF-2α) target activation and clinical outcomes in 942 patients with clear cell renal cell carcinoma

Meeting Abstract

Doshi, S. D.; Kuo, F.; Knezevic, A.; Kotecha, R. R.; Motzer, R. J.; Hakimi, A. A.; Voss, M. H.
Journal of Clinical Oncology (2024)

Fulltext@MSK | Save

Nivolumab plus ipilimumab (NIVO + IPI) vs sunitinib (SUN) for first-line treatment of advanced renal cell carcinoma (aRCC): Long-term follow-up data from the phase 3 CheckMate 214 trial

Meeting Abstract

Escudier, B.; McDermott, D. F.; Burotto, M.; Choueiri, T. K.; Hammers, H. J.; Plimack, E. R.; Porta, C.; George, S.; Powles, T.; Donskov, F.; more...
Journal of Clinical Oncology (2024)

Fulltext@MSK | Save

Nivolumab plus cabozantinib (N plus C) vs sunitinib (S) for previously untreated advanced renal cell carcinoma (aRCC): Results from 55-month follow-up of the CheckMate 9ER trial

Meeting Abstract

Bourlon, M. T.; Escudier, B.; Burotto, M.; Powles, T.; Apolo, A. B.; Shah, A. Y.; Porta, C.; Suárez, C.; Barrios, C. H.; Richardet, M.; more...
Journal of Clinical Oncology (2024)

Fulltext@MSK | Save

Post radical prostatectomy (RP) PSA outcomes following 6 versus 18 months of perioperative androgen receptor signaling inhibitors (ARSI) in men with localized high-risk prostate cancer: Results of Part 2 of a randomized phase 2 trial

Meeting Abstract

McKay, R. R.; Xie, W.; Yang, X.; Acosta, A.; Rathkopf, D. E.; Laudone, V. P.; Bubley, G.; Einstein, D. J.; Chang, P. T.; Wagner, A.; more...
Journal of Clinical Oncology (2024)

Fulltext@MSK | Save

Patient-reported health-related quality of life (HRQoL) in the randomized FORMULA-509 trial of salvage radiotherapy and 6 months of GnRH agonist with either bicalutamide or abiraterone acetate plus prednisone (AAP) and apalutamide (Apa) after radical prostatectomy (RP)

Meeting Abstract

Hoffman, K. E.; Nguyen, P. L.; Rathkopf, D. E.; Zurita, A. J.; Spratt, D. E.; Dess, R. T.; Liauw, S. L.; Szmulewitz, R. Z.; Einstein, D. J.; Bubley, G.; more...
Journal of Clinical Oncology (2024)

Fulltext@MSK | Save

Building a predictive model for outcomes with [177Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer using VISION data: Preliminary results

Meeting Abstract

Herrmann, K.; Gafita, A.; De Bono, J. S.; Sartor, A. O.; Chi, K. N.; Krause, B. J.; Rahbar, K.; Tagawa, S. T.; Czernin, J.; El-Haddad, G.; more...
Journal of Clinical Oncology (2024)

Fulltext@MSK | Save

Preclinical characterization of human Kallikrein 2 (hK2) as a novel target for the treatment of prostate cancer

Meeting Abstract

Shen, F.; Kelly, W. K.; Pandit-Taskar, N.; McDevitt, T.; Smith, R.; Menard, K.; Packman, K.; Chaudhary, R.; Rupnow, B.; Yu, M. K.; more...
Journal of Clinical Oncology (2024)

Fulltext@MSK | Save

Enzalutamide combination treatment (tx) suspension in men with high-risk biochemically recurrent (BCR) prostate cancer: Outcomes from EMBARK

Meeting Abstract

Freedland, S. J.; Sieber, P. R.; Gleave, M.; De Giorgi, U.; Mehlhaff, B. A.; Danila, D. C.; Dunshee, C.; Lallas, C. D.; Pliskin, M.; Tang, Y.; more...
Journal of Clinical Oncology (2024)

Fulltext@MSK | Save